Q-omics provides the consensus-scored DMTN profile across patient tissues and cancer cell-line models. DMTN expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DMTN is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, DMTN protein abundance shows 21,802 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, THCA, and GBM as cancer lineages where DMTN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DMTN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DMTN survival associations across molecular data types. DMTN RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DMTN RNA expression–survival associations across cancer types. High DMTN expression shows unfavorable associations in CESC and GBM, but favorable associations in ACC, KIRC, HNSC and OV. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DMTN RNA expression.
This table summarizes DMTN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DMTN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DMTN shows lower tumor expression in THCA, LUAD, BRCA, KIRC and LUSC and higher tumor expression in CHOL. The THCA box plot shows higher DMTN RNA expression in normal versus tumor tissue (log2 FC = −0.790, t-test p < 0.001).
This table shows molecular features associated with DMTN in patient tissues and cancer cell lines. In patient samples, DMTN shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DMTN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
